Expert: Oral At-Home Pill May Change the Game for COVID-19 Treatment

Video

Michael Frank, CEO of Revive Therapeutics, discussed the results of a phase 3 trial investigating bucillamine as an oral at-home pill for the treatment of COVID-19 symptoms.

Pharmacy Times interviewed Michael Frank, CEO of Revive Therapeutics, on a phase 3 trial investigating the use of bucillamine as an oral at-home pill for the treatment of COVID-19 symptoms.

During the discussion, Frank addressed why bucillamine was investigated as a potential treatment for COVID-19; whether bucillamine is already FDA-approved for other treatment targets; which COVID-19 symptoms bucillamine has shown the potential to treat; how bucillamine is unique as a treatment for COVID-19 symptoms; what the timeline for a potential FDA approval of bucillamine may be; whether the FDA has fast-tracked bucillamine’s expanded approval in a fashion similar to other COVID-19 treatments; and how bucillamine could change the landscape for the currently available COVID-19 treatments.

Related Videos
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
Medical team -- Image credit: Flamingo Images | stock.adobe.com
Semaglutide Ozempic injection control blood sugar levels | Image Credit: myskin - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.